AlertEdge.io
Single-Ticker Trade Brief
HSIC — Henry Schein Report Date: 2026-08-05 13:39 UTC  |  Sector: Health Care  |  Rating:
RISK DISCLAIMER: This is an momentum signal based on MACD and relative strength. Always validate before entering a position.
▲▲ Momentum Leader — MACD Cross + S&P 500 Outperformance

HSIC has a bullish MACD crossover on daily bars and is outperforming the S&P 500 by +18.34% over the past 63 trading days (HSIC +24.31% vs SPY +5.97%).

Ticker
HSIC
Entry Price
$90.0
vs S&P 500 (63d)
+18.34%
Ticker Return
+24.31%
Stop Loss
$86.01
TP1 Target
$95.99
TP2 Target
$99.98
Risk / Reward
1 : 1.5
Daily ATR stop
View HSIC Chart on TradingView

Key Price Levels

TP1 Target
$95.99
Breakout Level
$0
Entry
$90.0
Stop Loss
$86.01

Fundamentals

P/E Ratio
N/A
EPS (TTM)
N/A
Dividend Yield
0%
52-Wk High
N/A
52-Wk Low
N/A
Beta
N/A

Deep Dive Analysis — Claude Sonnet

ALERTEDGE TRADE BRIEF — HSIC (Henry Schein)

Signal Date: Current | Price: $90.00 | Sector: Health Care

SETUP

HSIC is breaking higher after a strong Q2 earnings beat, with daily MACD crossing bullish at 1.36 above a 1.23 signal line — a fresh momentum confirmation. Price closed near session highs at $90.00, holding above the open and suggesting controlled buying. The stock has outperformed SPY by over 18% in the past 63 trading days, indicating institutional accumulation and sustained relative strength. TP1 at $95.99 and TP2 at $99.98 offer defined upside with a stop at $86.01, roughly 4.4% below entry.

CATALYSTS

Q2 2026 earnings came in above both top and bottom line estimates, providing the fundamental fuel behind the recent 37% run. Henry Schein benefits from a dental and medical supply distribution model with recurring revenue characteristics. Healthcare sector resilience amid macro uncertainty adds a defensive tailwind. If the company is rebuilding margins post the 2023 cyberattack recovery cycle, analyst re-rating potential exists as visibility improves.

RISKS

The signal quality score of 50/100 is a direct red flag — this is not an early-in-move setup. A 37% run is already priced in, and news headlines are questioning whether the stock is cheap at current levels, suggesting stretched valuation sentiment. Fundamentals data is largely unavailable here, making it impossible to assess earnings quality, leverage, or forward growth. Volume on this bar is thin at 1,753, lacking conviction from a participation standpoint. The 1:1.5 risk/reward is below the 1:2 threshold preferred for extended setups. Any broader market selloff or healthcare policy headwind could accelerate a pullback toward the stop.

CONVICTION: Medium — The MACD confirmation and relative strength are real, but the low signal quality score, thin volume, and post-37%-run entry point meaningfully reduce the probability of a clean continuation without consolidation first.

Trade Parameters:

Entry: $90.00

Stop: $86.01

TP1: $95.99

TP2: $99.98

Risk/Reward: 1:1.5